Prime Therapeutics LLC v. Beatty
354 F. Supp. 3d 957
D. Me.2018Background
- Prime Therapeutics (a large PBM) sued former executive Ashley Beatty and her new employer Maxor, seeking a TRO/preliminary injunction to prevent Beatty from performing certain duties at Maxor while Prime alleges she will inevitably disclose Prime's confidential information/trade secrets and breach a post‑employment agreement.
- Beatty, a 20‑year PBM veteran, signed a 12‑month post‑employment covenant (non‑disclosure and non‑competition) with carve‑outs permitting work for competitors unless (a) it involves a "Competitive Product" or (b) it "would lead to the inevitable disclosure of Confidential Information."
- Beatty left Prime in Sept. 2018 and began phased employment at Maxor; Maxor structured four phased duties to limit potential exposure and received a copy of Beatty’s Agreement before hiring her.
- Prime identifies categories of claimed trade secrets (rebate strategy, pricing/margins, contract terms, analytics, strategic plans) and produced some labeled confidential documents (three PowerPoint decks, one redacted in the record).
- The court found limited direct competition between Prime and Maxor, differences in scale and services, disputed overlap in Beatty’s prior and new duties, no evidence Beatty retained or disclosed secret documents, and that Maxor implemented a phased plan limiting immediate access to sensitive functions.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Trade‑secret misappropriation / inevitable disclosure | Prime: Beatty had access to confidential pricing, rebate aggregation strategy, and strategic plans; her Maxor role will inevitably cause disclosure | Maxor/Beatty: duties are phased and distinct; limited competition; no evidence Beatty possesses or will use Prime secrets | Denied — Prime failed to meet heavy inevitable‑disclosure burden and is unlikely to prevail on DTSA/MUTSA claims |
| Breach of contract / enforceability of non‑compete | Prime: Beatty’s Maxor role renders her in breach of the Agreement’s general non‑compete | Beatty: Agreement expressly allows work for competitors unless it will cause inevitable disclosure or involve a Competitive Product; her role fits an exception | Denied — Agreement’s disjunctive carve‑outs mean Prime must show inevitable disclosure; it did not |
| Irreparable harm | Prime: threatened misappropriation of trade secrets constitutes irreparable harm warranting injunction | Defendants: no imminent misappropriation shown; monetary damages adequate; phased duties mitigate risk | Denied — Prime failed to show likelihood of immediate irreparable harm absent injunction |
| Temporary restraining order / immediacy | Prime: sought TRO to halt Beatty’s Maxor work immediately | Defendants: phase‑in and lack of imminent risk; some duties unchallenged through Nov. 25 | Denied — Rule 65 immediacy lacking because phase one runs through Nov. 25 and no immediate harm shown |
Key Cases Cited
- Winter v. Nat. Res. Def. Council, 555 U.S. 7 (2008) (preliminary injunction requires likelihood of irreparable harm and other equitable factors)
- Dataphase Sys., Inc. v. C L Sys., Inc., 640 F.2d 109 (8th Cir. 1981) (four‑factor preliminary‑injunction framework)
- Surgidev Corp. v. Eye Tech., Inc., 648 F. Supp. 661 (D. Minn. 1986) (discussing inevitable‑disclosure doctrine)
- Katch, LLC v. Sweetser, 143 F. Supp. 3d 854 (D. Minn. 2015) (describing heavy burden for inevitable‑disclosure showing)
- Int'l Bus. Machs. Corp. v. Seagate Tech., Inc., 941 F. Supp. 98 (D. Minn. 1996) (factors relevant to assessing risk of trade‑secret disclosure)
- Saban v. Caremark Rx, L.L.C., 780 F. Supp. 2d 700 (N.D. Ill. 2011) (PBM industry: rebate terms and reimbursement rates treated as confidential information)